Using a Low-Flow Extracorporeal Carbon Dioxide Removal (ECCO 2 R) System in the Management of Refractory Status Asthmaticus: A Case Series.
| Autor: | Fox S; From the Department of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama., Mehkri O; Department of Critical Care, Cleveland Clinic, Cleveland, Ohio., Latifi M; Department of Critical Care, Cleveland Clinic, Cleveland, Ohio., Krishnan S; Department of Critical Care, Cleveland Clinic, Cleveland, Ohio., Dill T; Clinical Operations, ALung Technologies Inc., Pittsburgh, Pennsylvania., Duggal A; Department of Critical Care, Cleveland Clinic, Cleveland, Ohio. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | ASAIO journal (American Society for Artificial Internal Organs : 1992) [ASAIO J] 2024 May 01; Vol. 70 (5), pp. e70-e74. Date of Electronic Publication: 2023 Oct 03. |
| DOI: | 10.1097/MAT.0000000000002064 |
| Abstrakt: | Rescue treatments for status asthmaticus remain limited. Current literature has mainly focused on using extracorporeal membrane oxygenation (ECMO) as a primary modality of care for these patients. Low-flow extracorporeal CO 2 removal (ECCO 2 R) systems are an attractive option to improve refractory hypercapnic respiratory acidosis because of status asthmaticus. This is a retrospective case series that describes the feasibility and efficacy of the use of a low-flow ECCO 2 R device, the Hemolung Respiratory Assist System, in patients with refractory hypercapnic respiratory failure because of status asthmaticus. Eight patients were treated with the Hemolung Respiratory Assist System in eight separate locations globally. Seven (88%) of the patients survived to discharge in this case series. Both CO 2 and pH resolution were seen in 6 hours. None of the ECCO 2 R runs were stopped because of mechanical- or device-related complications. One patient necessitated transition to ECMO. Low-flow ECCO 2 R systems is an effective option for resolution of refractory hypercapnia in status asthmaticus. Use of these systems are also associated with a survival rate of close to 90% in patients with status asthmaticus. (Copyright © ASAIO 2023.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|